Posted by Michael Wonder on 23 Aug 2022
Merck receives fast track designation from the US FDA for MK-2060, an investigational anti-coagulant therapy
23 August 2022 - Phase 2 study of MK-2060 currently on-going in people with end stage renal disease receiving haemodialysis.
Merck today announced that the US FDA has granted fast track designation for Merck’s investigational anticoagulant therapy MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end stage renal disease.
